View Author
patient study effect itf -1697 placebo -1697 reperfusion group measurement month infarction artery infarct size value function treatment perindopril trial heart investigator baseline reperfusion injury infarct difference ace inhibition 1.0 grade result injury brachial artery erasmus university rotterdam 0.1 inhibition analysis heart failure bene fit change p value brachial disease mortality angiotensin response artery disease 6 months center failure inhibitor dysfunction europa improvement cardiovasc 36 months treatment groups fmd measurement cardiol perindopril group enalapril diameter outcome placebo group blush bradykinin signi subgroup circulation netherland table enzyme rotterdam ischaemia study medication timi frame count europa trial image model safety itf -1697 dosage participant finding
2 Most Recent Publications
|
ACE inhibition and endothelial function: Main findings of PERFECT, a sub-study of the EUROPA trial
(Article)
Bots, M.L. Remme, W.J. Bassand, J-P. Cokkinos, D.V. Toutouzas, P. Eha, J. Erhardt, L. Erikssen, J. Grybauskas, R. Kalnins, U. Karsch, K. Sechtem, U. Lüscher, T.F. Keltai, M. Klein, W. Luescher, T. Mulcahy, D. Nieminen, M.S. Oto, A. Ozsaruhan, O. Paulus, W. Providencia, L. Riecansky, I. Fox, K.M. Ruzyllo, W. Santini, U. Tavazzi, L. Soler-Soler, J. Widimsky, P. Bertrand, M.E. Ferrari, R. Simoons, M.L. Grobbee, D.E. Aldershville, J. Hildebrandt, P. |
2007-08-01
|
|
The effect of ITF-1697 on reperfusion in patients undergoing primary angioplasty. Safety and efficacy of a novel tetrapeptide, ITF-1697
(Article)
Dirksen, M.T. Laarman, G-J. Giualiumi, G. Tonino, W.A.L. Tavazzi, L. Simoons, M.L. Hof, A.W.J. van 't Duncker, D.J.G.M. |
2004-03-01
|